COX-2 inhibition in upper aerodigestive tract tumors

Nasser K. Altorki, Kotha Subbaramaiah, Andrew J. Dannenberg

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Evidence continues to accumulate that cyclooxygenase-2 (COX-2), an inducible COX isoform, represents a potential pharmacological target for the prevention and treatment of cancer, including tumors affecting the upper aerodigestive tract. Studies in experimental models of these malignancies show that selective COX-2 inhibitors reduce tumor formation and growth. Clinical studies have been initiated to determine the chemopreventive effects of selective COX-2 inhibitors in patients with oral leukoplakia and Barrett's esophagus, and other studies are assessing the feasibility of incorporating these agents into existing treatment modalities for patients with locally advanced or metastatic cancer.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalSeminars in Oncology
Issue numberSUPPL. 7
StatePublished - Apr 2004

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'COX-2 inhibition in upper aerodigestive tract tumors'. Together they form a unique fingerprint.

Cite this